The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease

Mayo Clinic Histiocytosis Working Group

Research output: Contribution to journalReview article

Abstract

Histiocytic neoplasms, a rare and heterogeneous group of disorders, primarily include Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease. Due to their diverse clinical manifestations, the greatest challenge posed by these neoplasms is the establishment of a diagnosis, which often leads to a delay in institution of appropriate therapy. Recent insights into their genomic architecture demonstrating mitogen-activated protein kinase/extracellular signal–regulated kinase pathway mutations have now enabled potential treatment with targeted therapies in most patients. This consensus statement represents a joint document from a multidisciplinary group of physicians at Mayo Clinic who specialize in the management of adult histiocytic neoplasms. It consists of evidence- and consensus-based recommendations on when to suspect these neoplasms and what tests to order for the diagnosis and initial evaluation. In addition, it also describes the histopathologic and individual organ manifestations of these neoplasms to help the clinicians in identifying their key features. With uniform guidelines that aid in identifying these neoplasms, we hope to improve the awareness that may lead to their timely and correct diagnosis.

Original languageEnglish (US)
JournalMayo Clinic proceedings
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Erdheim-Chester Disease
Sinus Histiocytosis
Histiocytosis
Langerhans Cell Histiocytosis
Neoplasms
Mitogen-Activated Protein Kinases
Phosphotransferases
Therapeutics
Joints
Guidelines
Physicians
Mutation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{954aef3be4dd42a498882689d2a6b2c2,
title = "The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease",
abstract = "Histiocytic neoplasms, a rare and heterogeneous group of disorders, primarily include Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease. Due to their diverse clinical manifestations, the greatest challenge posed by these neoplasms is the establishment of a diagnosis, which often leads to a delay in institution of appropriate therapy. Recent insights into their genomic architecture demonstrating mitogen-activated protein kinase/extracellular signal–regulated kinase pathway mutations have now enabled potential treatment with targeted therapies in most patients. This consensus statement represents a joint document from a multidisciplinary group of physicians at Mayo Clinic who specialize in the management of adult histiocytic neoplasms. It consists of evidence- and consensus-based recommendations on when to suspect these neoplasms and what tests to order for the diagnosis and initial evaluation. In addition, it also describes the histopathologic and individual organ manifestations of these neoplasms to help the clinicians in identifying their key features. With uniform guidelines that aid in identifying these neoplasms, we hope to improve the awareness that may lead to their timely and correct diagnosis.",
author = "{Mayo Clinic Histiocytosis Working Group} and Gaurav Goyal and Young, {Jason R.} and Matthew Koster and Tobin, {W. Oliver} and Robert Vassallo and Ryu, {Jay H.} and Davidge-Pitts, {Caroline J.} and Hurtado, {Maria D.} and Aishwarya Ravindran and {Sartori Valinotti}, Julio and Nabila Bennani and Shah, {Mithun V.} and Rech, {Karen L.} and Go, {Ronald S.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.mayocp.2019.02.023",
language = "English (US)",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",

}

TY - JOUR

T1 - The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms

T2 - Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease

AU - Mayo Clinic Histiocytosis Working Group

AU - Goyal, Gaurav

AU - Young, Jason R.

AU - Koster, Matthew

AU - Tobin, W. Oliver

AU - Vassallo, Robert

AU - Ryu, Jay H.

AU - Davidge-Pitts, Caroline J.

AU - Hurtado, Maria D.

AU - Ravindran, Aishwarya

AU - Sartori Valinotti, Julio

AU - Bennani, Nabila

AU - Shah, Mithun V.

AU - Rech, Karen L.

AU - Go, Ronald S.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Histiocytic neoplasms, a rare and heterogeneous group of disorders, primarily include Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease. Due to their diverse clinical manifestations, the greatest challenge posed by these neoplasms is the establishment of a diagnosis, which often leads to a delay in institution of appropriate therapy. Recent insights into their genomic architecture demonstrating mitogen-activated protein kinase/extracellular signal–regulated kinase pathway mutations have now enabled potential treatment with targeted therapies in most patients. This consensus statement represents a joint document from a multidisciplinary group of physicians at Mayo Clinic who specialize in the management of adult histiocytic neoplasms. It consists of evidence- and consensus-based recommendations on when to suspect these neoplasms and what tests to order for the diagnosis and initial evaluation. In addition, it also describes the histopathologic and individual organ manifestations of these neoplasms to help the clinicians in identifying their key features. With uniform guidelines that aid in identifying these neoplasms, we hope to improve the awareness that may lead to their timely and correct diagnosis.

AB - Histiocytic neoplasms, a rare and heterogeneous group of disorders, primarily include Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease. Due to their diverse clinical manifestations, the greatest challenge posed by these neoplasms is the establishment of a diagnosis, which often leads to a delay in institution of appropriate therapy. Recent insights into their genomic architecture demonstrating mitogen-activated protein kinase/extracellular signal–regulated kinase pathway mutations have now enabled potential treatment with targeted therapies in most patients. This consensus statement represents a joint document from a multidisciplinary group of physicians at Mayo Clinic who specialize in the management of adult histiocytic neoplasms. It consists of evidence- and consensus-based recommendations on when to suspect these neoplasms and what tests to order for the diagnosis and initial evaluation. In addition, it also describes the histopathologic and individual organ manifestations of these neoplasms to help the clinicians in identifying their key features. With uniform guidelines that aid in identifying these neoplasms, we hope to improve the awareness that may lead to their timely and correct diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=85071315667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071315667&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2019.02.023

DO - 10.1016/j.mayocp.2019.02.023

M3 - Review article

AN - SCOPUS:85071315667

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

ER -